


# **Empiric Quinidine for Asymptomatic Brugada Syndrome- Preliminary Results of an International Registry**


**Arnon Adler<sup>1</sup>, MD; Louise RA Olde Nordkamp<sup>2</sup>, MD; Lia Crotti<sup>3</sup>, MD; Peter J. Schwartz<sup>3</sup>, MD; Silvia Castelletti<sup>3</sup>, MD; Boris Rudic<sup>4</sup>, MD; Rainer Schimpf<sup>4</sup>, MD; Christian Veltmann<sup>5</sup>, MD; Wataru Shimizu<sup>6</sup>, MD; Charles Antzelevitch<sup>7</sup>, PhD; Bernard Belhassen<sup>1</sup>, MD; Hanno L Tan<sup>2</sup>, MD PhD; Arthur AM Wilde<sup>2</sup>, MD PhD and Sami Viskin<sup>1</sup>, MD**

**From 1 Tel Aviv Souraski Medical Center and Sackler school of medicine, Tel Aviv University, Tel Aviv, Israel; 2 Heart Failure Research Centre, Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands; 3 University of Pavia and IRCCS Fondazione Policlinico San Matteo, Pavia, Italy ; 4 1st Department of Medicine-Cardiology, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany; 5 Hannover Medical School, Hannover, Germany; 6 Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; 7 Masonic Medical Research Laboratory, Utica, New York**

No disclosures



# Asymptomatic BrS- estimated risk



Percentage of asymptomatic patients with a spontaneous type 1 ECG that experience events (sudden cardiac death, appropriate implantable cardioverter-defibrillator discharge)

# Asymptomatic BrS- risk stratification

## Programmed electrical stimulation

Journal of the American College of Cardiology  
© 2012 by the American College of Cardiology Foundation  
Published by Elsevier Inc.

Vol. 59, No. 1, 2012  
ISSN 0735-1097/\$36.00  
doi:10.1016/j.jacc.2011.08.064

Heart Rhythm Disorders

### Risk Stratification in Brugada Syndrome

Results of the PRELUDE (PRogrammed  
ELectrical stimUlation preDICTive valuE) Registry

Silvia G. Priori, MD, PHD,\*†‡ Maurizio Gasparini, MD,§ Carlo Napolitano, MD, PHD,\*‡  
Paolo Della Bella, MD,|| Andrea Ghidini Ottonelli, MD,¶ Biagio Sassone, MD,#  
Umberto Giordano, MD,\*\* Carlo Pappone, MD,†† Giosuè Mascioli, MD,‡‡ Guido Rossetti, MD,§§  
Roberto De Nardis MD,|||| Mario Colombo, MS¶¶

*Pavia, Rozzano, Milano, Lido di Camaiore, Bentivoglio, Palermo, Ravenna, Bergamo, Cuneo,  
and Vicenza, Italy; and New York, New York*

# Asymptomatic BrS- risk stratification

Programmed electrical stimulation

Spontaneous type 1 pattern

Type 1 pattern in

QRS fragmentation


J point elevation

Signal averaged ECG


Exercise test

Repeated ECG

Holter




# ICD in BrS- complication rate



# Quinidine in BrS- efficacy data

In vitro arrhythmia suppression

ECG normalization in case reports



**A**

**B**



Alings et al; PACE 2001

# Quinidine in BrS- efficacy data

In vitro arrhythmia suppression

ECG normalization in case reports

Prevention of VF induction during EPS

Journal of the American College of Cardiology  
© 2004 by the American College of Cardiology Foundation  
Published by Elsevier Inc.

Vol. 43, No. 10, 2004  
ISSN 0735-1097/04/\$30.00  
doi:10.1016/j.jacc.2003.12.046

Hydroquinidin

Jean-Sylvain Hermida, M  
Geneviève Jarry, MD,\* I  
Jean-Luc Rey, MD,\* Br  
*Amiens and Paris, France*

**Circulation**  
JOURNAL OF THE AMERICAN HEART ASSOCIATION



**Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome**  
Bernard Belhassen, Aharon Glick and Sami Viskin

*Circulation*. 2004;110:1731-1737; originally published online September 20, 2004;  
doi: 10.1161/01.CIR.0000143159.30585.90



# Quinidine in BrS- efficacy data


In vitro arrhythmia suppression

ECG normalization in case reports

Prevention of VF induction during EPS

Preventing spontaneous arrhythmias in non-randomized trials

Effective in VF storm termination



# Quinidine- adverse reactions


Diarrhea & GI intolerance ~30%

Liver toxicity < 1%

Cytopenia < 1%

Cinchonism < 1%

Torsades de Pointes 2-8% (?)



# The Empiric Quinidine for Asymptomatic Brugada Syndrome International Registry

Asymptomatic patients with type 1 Brugada pattern

No evidence of structural heart disease


EPS is strongly discouraged

Initial dose: 600-900 mg hydroquinidine


48 hrs hospitalization during onset of therapy



# Preliminary results- number of patients




■ The Netherlands  
 ■ Italy  
 ■ Israel  
 ■ Germany  
 ■ Japan




**Total: 144**  
**Mean age: 42 (6-75)**


# Preliminary results





Symptoms



Family history




# Preliminary results




Diagnostic ECG

Genetics (n=67)




# Preliminary results- quinidine



# Preliminary results- follow up

1 adverse event in a mean  
follow up time of 2.4 years





A close-up photograph of a Cinchona tree branch. The image shows several large, dark green, glossy leaves with prominent veins. Interspersed among the leaves are clusters of small, light-colored flowers, some in full bloom and others as buds. The background is dark, making the green leaves and light flowers stand out.

Thank you

[brugadasyndrome.info](http://brugadasyndrome.info)

Cinchona tree